This inventor holds 2 USPTO granted patents. Top assignee: The University of Hong Kong. Active years: 2006-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006-2008
Title: Marie Chia-Mi Lin: Innovator in SARS Research
Introduction
Marie Chia-Mi Lin is a prominent inventor based in Hong Kong, CN. He has made significant contributions to the field of medical research, particularly in the area of viral infections. With a total of 2 patents, Lin's work focuses on innovative therapeutic agents for treating Severe Acute Respiratory Syndrome (SARS).
Latest Patents
Lin's latest patents include groundbreaking inventions related to the inhibition of SARS-associated coronavirus (SCoV) infection and replication through RNA interference. These inventions involve RNA interference (RNAi) molecules that are designed to inhibit the infection and replication of the hSARS virus. The RNAi molecules specifically target the replicase region of the hSARS virus, as well as combinations of different sites within the hSARS virus genes. Furthermore, the patents encompass methods for using these RNAi molecules to prevent and treat SARS, along with vaccines and kits that contain therapeutically effective amounts of the RNAi molecules.
Career Highlights
Marie Chia-Mi Lin is affiliated with The University of Hong Kong, where he conducts his research and development activities. His work has been instrumental in advancing the understanding and treatment of SARS, contributing to public health initiatives.
Collaborations
Lin has collaborated with notable researchers in his field, including Hsiang-Fu Kung and Ming-Liang He. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Marie Chia-Mi Lin is a key figure in the fight against SARS, with his innovative patents paving the way for new therapeutic approaches. His contributions to medical research continue to be invaluable in addressing viral infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
